The Middle Ages: Controversies in the Treatment of Adolescents and Young Adults With Leukemia
Over the past few decades, survival rates for pediatric patients with acute lymphocytic leukemia (ALL) have improved dramatically, with five-year survival rates now often exceeding 90 percent and 10-year survival rates exceeding 80 percent,...
Online Exclusives
Regional Hospital Consortiums Hope to Compete for Clinical Trials
In a bid to attract research funding while reducing administrative costs, small hospitals across the U.S. are joining together to create clinical trial consortiums....
Precision Therapy Proves Effective, but Costly
Precision medicine, or treatments tailored to individual patients based on genetic testing and other factors, has shown incredible promise in extending the lives of...
News
From the Blood Journals
Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis
Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...
Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis
Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
Multimedia
Pulling Back the Curtain: Vip Viprakasit, MD, DPhil
In more from our interview with Dr. Viprakasit, he speaks about the advantages of working in a limited-resource setting and the importance of international...
Let’s Get Cooking: Jonathan Hoggatt, PhD
In more from our interview with Dr. Hoggatt, he talks about the chocolate chip cookie experiment that started his obsession with cooking.
Pulling Back the Curtain: Richard W. Childs, MD
Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...
LentiGlobin Gene Therapy Possibly Safe for Severe Sickle Cell Disease
Interim data from a phase I study of LentiGlobin BB305 in patients with severe sickle cell disease (SCD) suggest that the gene therapy was...
On Location
From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal Residual Disease
During their presentations, MHM speakers will be asking the audience how they would respond to...
From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera
During their presentations, MHM speakers will be asking the audience how they would respond to...
From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL
During their presentations, MHM speakers will be asking the audience how they would respond to...
Researchers Define Long-Term Outcomes of Cancer-Associated Thrombosis
Patients diagnosed with cancer-associated thrombosis (CAT) remain at a high risk for recurrent venous thromboembolism...
Romiplostim Helps Patients With Glioblastoma and Thrombocytopenia Stay on Treatment
Temozolomide (TMZ) is part of the standard treatment for patients with glioblastoma, but the drug...
APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML
In a small phase IB/II trial presented at the 23rd Congress of the European Hematology...
Latest Headlines
ASH Directions
Nancy Berliner Named Next Editor-in-Chief of Blood, and more
ASH Launches New Sickle Cell Disease Clinical Trials Network
ASH has announced the launch of a clinical trials network in sickle cell disease (SCD) to...
Announcing the 2018 Honorific and Mentor Award Recipients, and more
Announcing the 2018 Honorific and Mentor Award Recipients!
ASH will recognize these distinguished leaders in hematology through awards and special lectures at the 60th ASH...
Lili Yang Wins $1.4 Million CIRM Quest Discovery Grant, and more
Remembering Thomas Michael Przybysz (1951-2018)
Thomas Michael Przybysz, MD, an oncologist, passed away on July 19, 2018, at the age of 66.
After serving in the...
Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...
Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors
NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...
NIH Awards $24 Million to UT Health San Antonio, and more
Remembering Michael C. Lill (1959-2018)
Michael C. Lill, MD, passed away on June 19, 2018, after a long battle with cancer. Dr. Lill was born...
The Middle Ages: Controversies in the Treatment of Adolescents and Young Adults With Leukemia
Over the past few decades, survival rates for pediatric patients with acute lymphocytic leukemia (ALL) have improved dramatically, with five-year survival rates now often...
Who Pays What, and Why?
From R&D to PBMs, a look at the U.S. approach to drug pricing
When it comes to setting drug prices, the U.S. is singular in...
Rethinking Burnout
Will solving physician burnout require sweeping changes to the U.S. health-care system?
About 15 years ago, during the first year of his fellowship, Tait Shanafelt,...
